Safety and Protective Efficacy of FF-3 Dry Powder in Healthy Subjects Infected With Influenza Challenge Strain
Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study are to determine the effect FF-3 in comparison to placebo in
subjects who are experimentally inoculated with a live, challenge strain of influenza A
virus.
Phase:
Phase 2
Details
Lead Sponsor:
Autoimmune Technologies, LLC
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)